ライフサイエンスコーパス: potency against

1 pounds, exemplified by 35 and 36, display nM potency against 12-LOX, excellent selectivity over relat

2 the majority of which exhibit submicromolar potency against 3'-end processing and strand transfer, t

3 ), was synthesized and tested for inhibitory potency against [(3)H]WIN35,428, [3H]citalopram, and [3H

4 d human 5-lipoxygenase (5-LOX) with improved potency against 5-LOX due to its reduction of the iron c

5 the clinically used raltegravir and retained potencies against a panel of IN mutants.

6 from milk and plasma had equal neutralizing potencies against a tier 1 virus (r = 0.65; P < 0.0001),

7 ical development that demonstrates excellent potency against a broad range of dimorphic and filamento

8 ht resulted in an improved antiproliferative potency against a colorectal cancer cell line.

9 Both compounds exhibited higher inhibitory potency against a COX-2 R120A variant than against the W

10 ed), with sub- and low micromolar inhibitory potency against a fluorogenic substrate.

11 for compound 5i) and low micromolar cellular potency against a mutant BRAF melanoma cell line, WM266.

12 Complex 1 exhibited unique potency against a panel of cancer cells, including cispl

13 ike the parent molecules, display no loss of potency against a panel of clinically important PI-resis

14 ne P2' moiety maintained excellent antiviral potency against a panel of multidrug-resistant HIV-1 str

15 inactive form kinase inhibitors due to equal potency against a panel of oncogenic activating mutation

16 Compound 12 retains its potency against a panel of Pf isolates with known mechan

17 50), 0.6 muM), which exhibited high in vitro potency against a panel of prostate and breast cancer ce

18 20q also had equivalent potency against a panel of single-drug resistant strains

19 ed systemically to mice and displays greater potency against a spectrum of human cancer cell lines th

20 compound 1C8 as displaying strong anti-HIV-1 potency against a variety of clinical strains in vitro.

21 l peptoid mimics which exhibit high in vitro potency against a variety of Gram-positive and Gram-nega

22 Inhibitor 3d maintains excellent potency against a variety of multi-PI-resistant clinical

23 hermore, this inhibitor maintains impressive potency against a wide spectrum of HIV including a varie

24 ogen-containing residue(s) had extraordinary potencies against ABCG2 (IC(50) < 150 nM).

25 ional constraints, to improve the inhibitory potency against active Src kinase.

26 activities with low micromolar to nanomolar potency against all four serotypes.

27 protease inhibitors, MK-5172 had exceptional potency against all HCV genotypes.

28 K inhibitors, PF-06463922 displayed superior potency against all known clinically acquired ALK mutati

29 trains or rather a global reduction in VRC01 potency against all strains.

30 eak inhibitors of GlyT1 likewise had similar potency against all three isoforms.

31 Although shishijimicin A and its extreme potencies against an array of cancer cell lines have bee

32 tations in a glycan-V3 bnAb modestly reduces potency against an autologous virus isolate.

33 new classes of antibiotics because of their potency against antibiotic-resistant pathogens.

34 ndoxifen (10), displayed elevated inhibitory potency against aromatase and enhanced affinity for estr

35 otent, similar to artemisinins, fast-killing potency against asexual blood stages that cause disease,

36 g of 26 compounds revealed 22 with nanomolar potency against axenically cultured bloodstream trypanos

37 nt to anti-CD19 immunotherapy, demonstrating potency against B-ALL comparable to that of CD19-CAR at

38 antagonists are described that exhibit good potency against B1 and high selectivity over B2.

39 ftazidime-avibactam demonstrated significant potency against Bcc and B. gladioli isolated from the sp

40 questration was less a factor in determining potency against BCR signaling.

41 e to its being long-acting and having a high potency against blood stage P. falciparum (Pf).

42 MRSA, and VanA and VanB VRE) and impressive potencies against both vancomycin-sensitive and vancomyc

43 entified five drugs with approximately equal potencies against both.

44 The inhibitor exhibits low nanomolar potency against both Aurora A and Aurora B enzymes, exce

45 om triazine to purine, improved the in vitro potency against both cruzain and rhodesain by 350-fold,

46 zinone (BTZ) inhibitors have shown nanomolar potency against both drug-susceptible and multidrug-resi

47 HCV NS5A inhibitor exhibiting submicromolar potency against both G-1a and G-1b replicons.

48 emporin B improves its membrane activity and potency against both Gram-negative and Gram-positive bac

49 cal models, we required inhibitors with good potency against both human and rodent isoforms.

50 Several SmSirt2 inhibitors showed potency against both larval schistosomes (viability) and

51 droquinolines (HHQs) that show low nanomolar potency against both pathogenic and transmissible intra-

52 The latter display high in vitro potency against both sensitive and resistant cancer cell

53 ain variant C184A showed the same inhibitory potency against both TACE forms as wild type TACE Pro.

54 Compound 3a displayed excellent potency against both the PARP-1 and PARP-2 enzymes with

55 inhibitor, Acriflavine, and demonstrate its potency against brain cancer.

56 om films at lower temperature exhibited high potency against breast cancer cells.

57 ar potency against CA II and CA IV, and with potency against CA I one order of magnitude better than

58 olar potency against CA IX and sub-nanomolar potency against CA II and CA IV, and with potency agains

59 Very potent pan-inhibitors with nanomolar potency against CA IX and sub-nanomolar potency against

60 in the range 1.73-10.5 muM and exhibited low potencies against CaE (9.8-26% inhibition at 20 muM).

61 mune surveillance and superior effector cell potency against cancer cells.

62 ole antifungal with an expanded spectrum and potency against Candida spp., Aspergillus spp., and othe

63 ole antifungal with an expanded spectrum and potency against Candida spp., Aspergillus spp., and othe

64 These compounds exhibit low nanomolar potency against caspase-3 with >120-fold selectivity ove

65 ernative lead candidate 4ab with a nanomolar potency against CDK2 and CDK9 and potent antiproliferati

66 nhibition of ATP-dependent kinases, and good potency against Cdks has been reported for representativ

67 azahypoxanthine skeleton exhibited nanomolar potencies against cell lines representing cancers with d

68 nds are more toxic than baicalein, and their potency against cell growth is compromised by the presen

69 both also enhanced anti-P-gp170 activity and potency against cell growth; however, the presence of P-

70 acid residues that greatly diminish the VCC potency against cells and investigated the interplay bet

71 its simpler analogues endowed with picomolar potencies against certain cancer cell lines.

72 entification of compounds with low picomolar potencies against certain cancer cell lines.

73 nalogues (e.g., Tb14), some with exceptional potencies against certain cell lines [e.g., Tb32 with IC

74 any of the compounds tested showed excellent potency against chloroquine sensitive and resistant stra

75 Kalihinol B shows similarly high potency against chloroquine-resistant Plasmodium falcipa

76 ility of 1 was associated with (i) decreased potency against cIAP2 and affinity for XIAP BIR3 and (ii

77 ave arrived at two leads possessing improved potency against clinical VRE strains from MIC = 2 mug/mL

78 amides as HCV protease inhibitors addressing potency against clinically relevant resistant variants.

79 a number of derivatives retained acceptable potency against CPT-1.

80 s (BKIs) that have nearly identical in vitro potency against Cryptosporidium but display divergent PK

81 design additional analogues with inhibitory potency against CYP2C19.

82 e-2-carboxamides with low nanomolar in vitro potency against DHODH from P. falciparum, P. vivax, and

83 ate important determinants for Btk inhibitor potency against different signaling pathways and provide

84 Given its relatively broad spectrum and potency against diverse Gram-negative pathogens, CHIR-09

85 part, but also displayed improved inhibitory potency against DNA methyltransferase 1, improved select

86 e newly synthesized compounds exhibited high potency against DNA-PK and potentiated the cytotoxicity

87 necarbonylcinnamoyl groups brings about high potency against drug efflux mediated by P-glycoprotein (

88 3-position of P2 quinoxaline maintain better potency against drug resistant variants, likely due to r

89 esent a novel class of compounds with strong potency against drug sensitive and resistant P. falcipar

90 HSP targeted DOC conjugates exhibited high potency against DU145 cells with an IC(5)(0) of 2.4 nM.

91 Indole 24 is nontoxic and showed increased potency against dynamin I and II in vitro and in cells (

92 behavior of She1 along microtubules and its potency against dynein.

93 which demonstrated excellent selectivity and potency against effector human memory T cells (subnanomo

94 mor cell lines and showed superior antitumor potency against EGFR-positive tumor xenografts as compar

95 S138A and E148A in the same peptide retained potency against ENF-escape mutants.

96 II and III maintained potency against enzalutamide-resistant (Enz-R) mutant AR

97 l profile is explored in terms of inhibitory potency against enzymes of the PfFAS-II pathway.

98 The potency against Epstein-Barr virus (EBV) was assay-depen

99 ve bacteria while nevertheless enhancing its potency against Escherichia coli.

100 rs has been developed with greatly increased potency against FabI-containing organisms.

101 quester Y551 was an important determinant of potency against FcepsilonR signaling as Y551 sequesterin

102 Star 27 maintains potency against FLT3 in proliferation assays of FLT3-tra

103 -folate and demonstrated its selectivity and potency against folate receptor 1 (FOLR1)-expressing ova

104 Furthermore, CCG205432 retains similar potency against fully infectious virus in cultured human

105 set of furin inhibitors with nanomolar range potency against furin when assayed in a biochemical clea

106 discovered to date that exhibits equivalent potency against FXIa.

107 idity of BILN 2061, while conferring greater potency against genotype 1, rendered it more sensitive t

108 in inhibitor 41H (GSK2236805) supported high potency against genotypes 1a and 1b as well as in genoty

109 ric inhibitors, the 93-series, shows greater potency against GluN1-GluN2B NMDA receptors in such low

110 ed to 4-methyl hexanoic acid, having similar potency against Gram negative and Gram positive pathogen

111 ative chemistry efforts improved biochemical potency against gram-negative isozymes 300-fold and affo

112 zation of the LPS barrier, thereby improving potency against Gram-negative pathogens.

113 Its potency against Gram-negative strains was comparable (on

114 Synthetic araiosamines were shown to exhibit potency against Gram-positive and -negative bacteria des

115 ibitors and explained their relative lack of potency against gram-positive GlmU isozymes.

116 ve inhibitor, CCG258747, which has nanomolar potency against GRK2 and excellent selectivity over othe

117 all current PIs exhibit significantly lower potency against GT-3.

118 maintaining sub-micromolar to low micromolar potency against HAdV.

119 The combination of high potency against HCMV deltaAla protease and high human pl

120 Compound 5 g shows low nanomolar inhibitory potency against HDAC6 and a selectivity of approximately

121 omolar concentrations and displays excellent potency against hepatitis B virus (HBV) and varicella-zo

122 type-specific immune responses with limited potency against heterologous viral strains and genotypes

123 potency but dramatically lowered inhibition potency against hGV and hGX sPLA(2)s.

124 The data show a modest trend for lower potency against higher expressing lines.

125 pounds show single-digit nanomolar antiviral potencies against HIV vectors that carry wild-type (WT)

126 T-derived 1,2,3-triazoles with submicromolar potencies against HIV-1.

127 Several ProTide compounds showed substantial potency against HIV-1 at low micromolar range while the

128 to the discovery of molecules with improved potency against HIV-1 RT.

129 lecule HIV capsid inhibitor with exceptional potency against HIV-2 and all major HIV-1 types, includi

130 several bnMAbs remarkable for their in vitro potency against HIV.

131 kappaM-RIIIJ is a determinant of its higher potency against hKv1.2.

132 GHP-88309 showed nanomolar potency against HPIV3 isolates in well-differentiated hu

133 Although both compounds display similar potencies against human topoisomerase IIalpha and IIbeta

134 towards pre-clinical development, given its potency against human and mouse cGAS.

135 The most active agent, 2j, showed high potency against human cancer cells with IC50s ranging fr

136 ry carbon atom, with up to 40-fold increased potency against human class I HDACs (e.g., JT86, IC(50)

137 Compound 2 had inhibitory potency against human DHFR similar to N-[4-[2-(amino-3,4

138 ol-5-yl)pyrogallol, with a 300-fold improved potency against human GS.

139 abrogating the previously reported antiviral potency against human immunodeficiency virus (HIV-1).

140 3b would preserve transport selectivity and potency against human tumor cells, 3b regioisomers with

141 These compounds show modest to high potency against human umbilical vein endothelial cell pr

142 zed pyrrolyl derivatives that exhibited good potency against IN and a moderate inhibition of the RNas

143 5-substituted analogs exhibit low micromolar potency against in vitro cultures of drug-resistant and

144 ning only a salicylic acid showed inhibitory potency against IN, none of the compounds containing onl

145 up (e.g. 5-13) showed significant inhibitory potency against IN, while the presence of either salicyl

146 ion of an emerging lead compound, displaying potency against intracellular bacteria in the low microm

147 available JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).

148 iscovered which exhibit in vitro and in vivo potency against key respiratory pathogens.

149 erating compound E67-2) has no effect on the potency against KIAA1718 but, unexpectedly, lost inhibit

150 kemic cell lines expressing these mutations (potency against KIT D816Y >> D816F > D816V).

151 ted extraordinary neutralization breadth and potency against large panels of cross-clade pseudoviruse

152 , a first generation lead with low nanomolar potency against life MeV and attractive physical propert

153 gesting that neratinib possessed therapeutic potency against liver fibrosis and the potential for app

154 igands demonstrated significant antiandrogen potency against LNCaP and Enzalutamide-resistant prostat

155 These compounds display enhanced potency against LpxC in enzymatic assays and superior an

156 ion with front-line antibiotics enhanced the potency against M. tuberculosis by more than 100-fold, t

157 d TAC-derived analogues have shown increased potency against M. tuberculosis.

158 Most of the compounds showed micromolar potency against malaria, with seven of them having IC50

159 ear whether these antibodies exhibit similar potency against mature dendritic cell (mDC)-mediated HIV

160 g a (14)C-lactate transport assay, and their potency against MCT1-expressing human tumor cells was es

161 Overall, TMC114's potency against MDR viruses is likely a combination of i

162 These reverse amides also exhibited less potency against monoamine oxidase (MAO) enzymes and thus

163 ise contribute to neutralization breadth and potency against most primary virus strains.

164 drophobic surface, providing a basis for its potency against MRSA known to deploy positively charged

165 uinolone-class compounds that have increased potency against Mtb and the ability to overcome resistan

166 This inhibitor maintained near full potency against multi-PI-resistant clinical HIV-1 varian

167 of Aurora kinase inhibitor 14a revealed that potency against multidrug-resistant cell lines was compr

168 f these taxoids exhibited exceptionally high potency against multidrug-resistant cell lines, and seve

169 C220, KW-2449, sorafenib, and sunitinib) for potency against mutant and wild-type FLT3, as well as fo

170 These changes allow it to retain potency against mutations that otherwise would render th

171 e effect in patients despite displaying poor potency against Mycobacterium tuberculosis (Mtb) in vitr

172 2-carboxamide analog (1), had low micromolar potency against Mycobacterium tuberculosis (Mtb), high m

173 This analogue exhibited moderate inhibitory potency against Mycobacterium tuberculosis thymidylate k

174 one with improved in vitro and intracellular potency against Mycobacterium tuberculosis, including mu

175 These compounds showed high in vitro potency against Mycobacterium tuberculosis, the etiologi

176 that demonstrated highly promising in vitro potency against Mycobacterium.

177 f protoxin II-NHCH3, a molecule with greater potency against Nav1.7 channels (IC50=42 pM) than the or

178 ctive metabolite of 1, has retained in vitro potency against newly emerging antifolate-resistant mala

179 ynthesis of LCL204, with enhanced inhibitory potency against NMT1.

180 An unsubstituted amide bond is necessary for potency against nNOS.

181 PF-06463922 exhibited subnanomolar cellular potency against oncogenic ROS1 fusions and inhibited the

182 l of 30 kinases, and found to have nanomolar potency against only JAK3.

183 These compounds were assessed for their potency against P-gp and another transporter (MRP1), for

184 Th17 clones and rhIL-26 lacked antimicrobial potency against P. acnes.

185 bination of poor plasma exposure and reduced potency against P. berghei DHODH.

186 was to identify indolequinones with improved potency against pancreatic cancer and to define their me

187 Despite demonstrating high in vitro potency against pathogenic multidrug-resistant bacteria,

188 Several new PIs exhibit nanomolar antiviral potencies against patient-derived wild-type viruses from

189 of 8 resulted in a 9- and 8-fold increase in potency against pcDHFR and tgDHFR, respectively.

190 ty in rats, dogs, and monkeys while the high potency against PDE5 and desirable selectivity versus ot

191 Medicinal chemistry optimization of the potency against Pf and ADME properties resulted in the i

192 ounds, 7 and 8 showed the highest inhibitory potency against Pf enoyl-ACP-reductase (PfFabI), followe

193 the basis for developing novel PIs with high potency against PI-resistant HIV-1 variants with a high

194 properties and PK parameters, low nanomolar potency against PI3Kalpha and mTOR, and excellent inhibi

195 the most selective inhibitor with excellent potency against pjDHFR.

196 We sought to identify compounds with higher potency against Plasmodium DHODH while showing greater s

197 ances over azithromycin in vitro in terms of potency against Plasmodium falciparum (over 100-fold) an

198 e (23) analogues exhibited improved in vitro potency against Plasmodium falciparum compared to the pa

199 s of arterolane (OZ277) had little effect on potency against Plasmodium falciparum in vitro.

200 siense and Leishmania donovani and nanomolar potency against Plasmodium falciparum.

201 , transition state analogs that exhibit high potency against PNP in the malaria parasite Plasmodium f

202 alogues with improved antibacterial in vitro potency against polymyxin resistant recent clinical isol

203 , known as Hoechst nuclear stains, with high potency against poxvirus infection.

204 d that possesses increased cytotoxicological potency against prokaryotic cells compared to eukaryotic

205 ) = 58 muM), which has reasonable inhibition potency against Pseudomonas aeruginosa TMK (PaTMK), was

206 o)benzoic acid (27), showing a submicromolar potency against purified CK2alpha (IC(50) = 0.6 muM).

207 e rounds of optimization to improve compound potency against purified enzyme and intracellular Plasmo

208 mpound against the parasite enzymes with its potency against rat liver DHFR.

209 plasmin in the subnanomolar range, and their potency against related trypsin-like serine proteases in

210 ately improved ( approximately 2- to 4-fold) potencies against replicating Mycobacterium tuberculosis

211 dition to the antiviral inhibitors with high potency against resistant strains of HIV.

212 indicative of once-daily dosing and superior potency against resistant viral strains.

213 ci (VRE), and fluoroquinolones with improved potency against respiratory pathogens and multidrug-resi

214 y reported; however, the greater decrease in potency against rlDHFR compared to pcDHFR and tgDHFR res

215 1 RT in the micromolar range while retaining potency against RT variants carrying one of three major

216 nds studied, 46a,b showed not only very good potency against RXRalpha (K(i) = 6 nM) but was also foun

217 n of natural products that display nanomolar potency against select isoforms of eukaryotic voltage-ga

218 the MPER antigens but also in neutralization potency against sensitive HIV-1.

219 Compound 40 exhibits high potency against several BRAF(V600E)-dependent cell lines

220 natural product with reported sub-nanomolar potency against several cancer cell lines.

221 revir showed submicromolar-to-low-micromolar potency against several recently circulating neurotropic

222 an produced antibodies retaining exceptional potency against some subtype C viruses.

223 ells in monolayers, 033-F had notably weaker potency against spheroids despite potency levels of MMAE

224 in-based inhibitors with 9-18-fold increased potency against Staphylococcus aureus (Sa) and Bacillus

225 rotein kinase inhibitors that show nanomolar potency against T. brucei bloodstream forms, Leishmania

226 lead compound, 17b, that exhibited nanomolar potency against T. brucei with excellent selectivity for

227 ity in cell-free assays, and a submicromolar potency against T315I Bcr-Abl expressing cells.

228 diaminopyrimidine-based inhibitors with good potency against T790M-containing mutants of EGFR, high s

229 Additionally, compound 32 shows potency against TAF1, a bromodomain-containing transcrip

230 effective compound, 22 (MN-64), showed 6 nM potency against tankyrase 1, isoenzyme selectivity, and

231 cidal activity was developed on the basis of potency against TbcatB and various calculated physical p

232 d metabolic stability while maintaining high potency against TbrPDEB1 and T. brucei.

233 ification of novel compounds with inhibitory potency against TGK.

234 yrosine kinase inhibitors with low nanomolar potencies against the members of the VEGFR and PDGFR kin

235 These antibodies exhibited high potency against the 2009 virus in vitro, and one exerted

236 ounds from this series demonstrated in vitro potency against the 3D7 and Dd2 strains of P. falciparum

237 high bioavailability and its nanomolar-range potency against the antiangiogenic receptor tyrosine kin

238 8b, and 11b showed good in vitro inhibition potency against the CAs IX and XII, with K(I) values in

239 lular calcium mobilization and a much higher potency against the chemerin(149-157) nonapeptide-induce

240 ts have shown a 40-fold and 200-fold loss in potency against the CRFR1 H199V and M276I mutant recepto

241 ized compounds, 22 showed excellent in vitro potency against the cultured parasites (W2 IC(50) = 13 n

242 tifolate, trimethoprim, because of a lack of potency against the dihydrofolate reductase enzyme.

243 refore, the retained and improved inhibitory potency against the drug-resistant variants A156T, D168V

244 The series showed broad potency against the drug-resistant W2 strain of P. falci

245 taxoids exhibited virtually no difference in potency against the drug-sensitive and drug-resistant ce

246 Until recently, despite achieving high potency against the enzyme, these efforts have been thwa

247 , have demonstrated profound selectivity and potency against the FLT3 target, and are currently being

248 based on paroxetine, demonstrates increased potency against the GRK2 subfamily and favorable pharmac

249 Compound 4t has excellent potency against the HCV 1b replicon, with an EC50 = 2 nM

250 in 5A (NS5A), such as daclatasvir, have high potency against the hepatitis C virus (HCV).

251 ic nitrogen while still maintained excellent potency against the hGnRH receptor.

252 these compounds show low to high inhibitory potency against the human CYP17 enzyme.

253 ike growth factor receptor kinase with equal potency against the insulin receptor is described.

254 on of inhibitors with significantly improved potency against the key resistant variants and with incr

255 he optimized compounds display low nanomolar potency against the mast cell target and several hundred

256 re were prepared that possessed subnanomolar potency against the NS3 protease in a subgenomic replico

257 pectrum antimicrobial activity, and enhanced potency against the opportunistic human pathogen Acineto

258 revealed that an inhibitor with insufficient potency against the p110beta isoform was less effective

259 ies of noncovalent inhibitors with nanomolar potency against the papain-like protease (PLpro) from th

260 Compound 22b displayed excellent potency against the PARP-1 enzyme with a K(i) of 1 nM an

261 yclic inhibitors displayed 20-50-fold higher potency against the PDF active site (K(I) as low as 70 p

262 be nzothiophen-1-yl]acetamide) combined high potency against the target enzyme (DNA-PK IC = 8 nM) wit

263 These exhibit enhanced potency against the target in binding and functional ass

264 on of the series scaffold to further enhance potency against the target while also improving pharmaco

265 ciating rate, thus increasing its anti-HIV-1 potency against the temporarily exposed target in NHR an

266 icinal chemistry campaign to achieve greater potency against the trypanosome.

267 l group of Cys181 that helps the drug retain potency against the Tyr181Cys mutation.

268 This level of potency against the unactivated form of VLA-4 was shown

269 ionale to the drastic decrease in inhibitory potency against the V27A variant.

270 This loss of potency against the yeast enzyme correlated with a compl

271 ed against the full-length human enzyme, the potency against the yeast enzyme has decreased significa

272 rmation to that of IGF-1R/IR, explaining the potency against these two structurally distinct kinase f

273 ynergistic effect and significantly enhanced potency against three esophageal adenocarcinoma cell lin

274 hienopyrimidinone derivatives with nanomolar potency against TrmD in vitro and discovered a novel act

275 ycin (mTOR) that also showed high inhibitory potency against Trypanosoma brucei cultures.

276 NCI 60 human tumor cell line and significant potency against tubulin assembly (IC50 0.812 muM).

277 cells), demonstrating 3- to 10-fold greater potency against tumor cell lines when compared with norm

278 ession correlates negatively with phagocytic potency against tumour cells, and blockade of PD-1-PD-L1

279 nylacetamido moiety in order to increase the potency against (V600E)BRAF compared to CRAF.

280 s analogs with 3~8-fold and 2~4-fold greater potency against vancomycin resistant Enterococcus faecal

281 /= 0.008 to 0.12 mug/mL), including enhanced potency against vancomycin-resistant enterococci.

282 The V-V series displayed the greatest potency against vancomycin-susceptible organisms and van

283 ainst HIV strains with wild-type RT but lose potency against variants with single Y181C and double K1

284 le round replication assay and have improved potency against vectors harboring the major forms of dru

285 The molecule was evaluated both in vitro for potency against VEGF and in ocular VEGF-driven efficacy

286 scovery of second generation inhibitors with potency against viral strains bearing drug resistant IN

287 ough these prototype inhibitors have similar potencies against wild-type c-Met (K(i) = 6-7 nM), signi

288 Both compounds displayed low nanomolar potency against wild type HIV in the presence of human s

289 the higher affinity T20 variant had similar potency against wild type HIV-1.

290 Such adaptations appear to be critical for potency against wild-type and a wide range of drug-resis

291 cussed, focusing on optimization of cellular potency against wild-type and drug resistant parasites a

292 on of 8e (MK-4965), which has high levels of potency against wild-type and key mutant viruses, excell

293 n a high throughput screening, with moderate potency against wild-type GCase.

294 critical pharmacophore for enhanced in vitro potency against wild-type hepatitis C replicons and know

295 small-molecule SRC/ABL inhibitors also have potency against WT KIT kinase.

296 31N with potencies greater than amantadine's potency against WT M2.

297 This compound possessed excellent potency against WT RT and key clinically observed RT mut

298 w analogue compound 2 that maintains greater potency against Y181C and K103N/Y181C variants and bette

299 , we now demonstrate that KP1019 retains its potency against yeast carrying the hypermorphic alleles

300 th ZIKV(C) and ZIKV(M) in hNPCs, with higher potency against ZIKV(C)-induced apoptosis.